Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director comp.
Senti Biosciences, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
08/11/2023 8-K Quarterly results
08/10/2023 8-K Asset disposition
Docs: "Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners – Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies –"
05/09/2023 8-K Quarterly results
Docs: "Senti Bio Announces First Quarter 2023 Results and Pipeline Updates – New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy&#59; remains on track for IND submission and clearance in 2H 2023 –"
03/22/2023 8-K Quarterly results
Docs: "Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights - SENTI-202 on track to submit an Investigational New Drug application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS -"
01/27/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies&#59; Updates Cash Runway Guidance – R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors –",
"CORPORATE PRESENTATION"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRESENTATION"
09/30/2022 8-K Quarterly results
08/31/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "ChEF PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT"
08/15/2022 8-K Quarterly results
07/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/19/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/15/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/10/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Form of Amendment No. 1 to Non-Redemption Agreement, by and among Dynamics Sponsor LLC, Dynamics Special Purpose Corp. and the undersigned investor",
"Form of Amendment No. 1 to Non-Redemption Agreement, by and among Dynamics Sponsor LLC, Dynamics Special Purpose Corp. and the undersigned investor"
02/15/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K"
12/20/2021 8-K Quarterly results
12/10/2021 8-K/A Quarterly results
12/10/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy